Publications by authors named "Mark Leick"

Claim this Profile
I
Isolated oral CAR T cell lymphoma after tisagenlecleucel.
Mark B Leick, Marcela V Maus

Mol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer.
Sangwoo Park, Cassidy E Ho, Eli P Darnell, Alexandra N Wolff, Hana Takei, Mark B Leick

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models.
Filippo Birocchi, Antonio J Almazan, Aiyana Parker, Amanda A Bouffard, Sadie Goncalves, Mark B Leick

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer.
Alexander Armstrong, Graziella van der Plancke, Sae Nishiguchi, Diego Salas-Benito, Amanda A Bouffard, Mark B Leick

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled primate screen finds that MYD88-CD40 boosts CAR-T.
Mark B Leick

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma.
Nelson H Knudsen, Giulia Escobar, Felix Korell, Tamina Kienka, Celeste Nobrega, Mark B Leick

Nature· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.
Melissa R Hines, Tristan E Knight, Kevin O McNerney, Mark B Leick, Tania Jain

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time.
Diego Salas-Benito, Filippo Birocchi, Sangwoo Park, Cassidy E Ho, Alexander Armstrong, Mark B Leick

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.
Valentina M Supper, Hannah Donner, Filippo Birocchi, Alexandra Bratt, Giulia Escobar, Mark B Leick

Cancer Immunol Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.
Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-γ-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models.
Stefanie R Bailey, Hana N Takei, Giulia Escobar, Michael C Kann, Amanda A Bouffard, Mark B Leick

Sci Transl Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
Rishab Ramapriyan, Fred G Barker, Leland G Richardson, Jing Sun, Gust Vandecandelaere, Mark B Leick

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.
Matthew J Frigault, Ning Yao, Trisha R Berger, Marc Wehrli, Kathleen M E Gallagher, Mark B Leick

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
Harrison J Silva, Grace Martin, Filippo Birocchi, Marc Wehrli, Michael C Kann, Mark B Leick

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated With Increased Risk of Contamination in Bone Marrow Transplants.
Eashwar Somasundaram, Rachel Gill, Nicole Hartford, Kerry Collier, Steven M McAfee, Mark Leick

Transplant Cell Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Matthew J Frigault, Charlotte E Graham, Trisha R Berger, Julie Ritchey, Nora K Horick, Mark B Leick

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.
Felix Korell, Michael L Olson, Diego Salas-Benito, Mark B Leick, Rebecca C Larson

Sci Transl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Marc Wehrli, Samantha Guinn, Filippo Birocchi, Adam Kuo, Yi Sun, Mark B Leick

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.
Won-Ho Lee, Charlotte E Graham, Hadley R Wiggin, Hannah K Nolan, Kiana J Graham, Mark B Leick

Cytometry B Clin Cytom· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stealth transgenes enable CAR-T cells to evade host immune responses.
Korneel Grauwet, Trisha Berger, Michael C Kann, Harrison Silva, Rebecca Larson, Mark B Leick

J Immunother Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
Bryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, Mark B Leick, Christopher W Mount

N Engl J Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7.
Michael C Kann, Emily M Schneider, Antonio J Almazan, Isabel C Lane, Amanda A Bouffard, Mark B Leick

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic retargeting of E3 ligases to enhance CAR T cell therapy.
Isabel C Lane, Gabriele Kembuan, Jeannie Carreiro, Michael C Kann, William Lin, Mark B Leick

Cell Chem Biol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide.
Daniel J Ikeda, Zachariah DeFilipp, Kerry Collier, Yi-Bin Chen, Bimalangshu R Dey, Mark B Leick

Bone Marrow Transplant· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Justin C Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V Cervantes

Mol Ther Oncolytics· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis